[{"orgOrder":0,"company":"Orion Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Orion Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Orion Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Biotechnology \/ Bayer","highestDevelopmentStatusID":"10","companyTruncated":"Orion Biotechnology \/ Bayer"},{"orgOrder":0,"company":"IQWiG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"IQWiG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"IQWiG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IQWiG \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Orion Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Orion Pharma"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Darolutamide","moa":"Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Preclinical","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Essa Pharma \/ Bayer","highestDevelopmentStatusID":"4","companyTruncated":"Essa Pharma \/ Bayer"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Essa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Bayer","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corporation \/ Bayer"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Orion Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Orion Corporation"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Coated Tablet","sponsorNew":"Bayer AG \/ Orion Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Orion Corporation"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Orion","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Orion"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Bayer","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corporation \/ Bayer"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen","graph1":"Oncology","graph2":"Approved","graph3":"Orion Biotechnology","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Biotechnology \/ Bayer","highestDevelopmentStatusID":"12","companyTruncated":"Orion Biotechnology \/ Bayer"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen","graph1":"Oncology","graph2":"Approved","graph3":"Orion Biotechnology","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orion Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen","graph1":"Oncology","graph2":"Approved","graph3":"Orion Biotechnology","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orion Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen","graph1":"Oncology","graph2":"Approved","graph3":"Orion Biotechnology","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orion Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corporation \/ Bayer AG"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corporation \/ Bayer AG"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corporation \/ Bayer AG"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Darolutamide","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Telix Pharmaceuticals"},{"orgOrder":0,"company":"Celcuity","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Gedatolisib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celcuity","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celcuity \/ Bayer AG","highestDevelopmentStatusID":"7","companyTruncated":"Celcuity \/ Bayer AG"},{"orgOrder":0,"company":"Celcuity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Gedatolisib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celcuity","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celcuity \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Celcuity \/ Not Applicable"},{"orgOrder":0,"company":"Celcuity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Gedatolisib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celcuity","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celcuity \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Celcuity \/ Not Applicable"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Darolutamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Thermo Fisher Scientific \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Thermo Fisher Scientific \/ Bayer AG"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bayer AG \/ Orion Corporation","highestDevelopmentStatusID":"14","companyTruncated":"Bayer AG \/ Orion Corporation"}]
Find Clinical Drug Pipeline Developments & Deals for Darolutamide
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
